{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:57Z","timestamp":1786118937811,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/olq.0b013e31816766af","type":"journal-article","created":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T03:19:06Z","timestamp":1213067946000},"page":"577-582","source":"Crossref","is-referenced-by-count":20,"title":["Phase I Clinical Trial of Repeat Dose Terameprocol Vaginal Ointment in Healthy Female Volunteers"],"prefix":"10.1097","volume":"35","author":[{"given":"Niharika","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dalby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210213","doi-asserted-by":"crossref","first-page":"11239","DOI":"10.1073\/pnas.92.24.11239","article-title":"Inhibition of human immunodeficiency virus type I transcription and replication by DNA sequence-selective lignans.","volume":"92","author":"Gnabre","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-10-20210213","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1021\/jm970819w","article-title":"Antiviral activity of methylated nordihydroguaiaretic acid (I) synthesis, structural identification and inhibition of Tat regulated HIV transactivation.","volume":"41","author":"Hwu","year":"1998","journal-title":"J Med Chem"},{"key":"R3-10-20210213","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jmb.2005.04.001","article-title":"Influence of ions hydration and the transcriptional inhibitor P4N on conformations of the Sp1 binding site.","volume":"349","author":"Dohm","year":"2005","journal-title":"J Mol Biol"},{"key":"R4-10-20210213","first-page":"5499","article-title":"Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo.","volume":"61","author":"Heller","year":"2110","journal-title":"Cancer Res"},{"key":"R5-10-20210213","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0304-3835(01)00560-2","article-title":"Tetra-O-methyl nordihydroguaiaretic acid inhibits melanoma in vivo.","volume":"171","author":"Lambert","year":"2001","journal-title":"Cancer Lett"},{"key":"R6-10-20210213","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(00)00089-9","article-title":"Inhibition of human papillomavirus 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives.","volume":"47","author":"Craigo","year":"2000","journal-title":"Antiviral Res"},{"key":"R7-10-20210213","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(02)00165-1","article-title":"Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-Nordihydro-guaiaretic acid.","volume":"58","author":"Park","year":"2003","journal-title":"Antiviral Res"},{"key":"R8-10-20210213","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1021\/jm980182w","article-title":"Antiviral activities of methylated nordihydroguaiaretic acid. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.","volume":"41","author":"Chen","year":"1998","journal-title":"J Med Chem"},{"key":"R9-10-20210213","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2007.08.074","article-title":"Phase I\/II clinical safety studies of terameprocol vaginal ointment.","volume":"107","author":"Khanna","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R11-10-20210213","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R13-10-20210213","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMp078053","article-title":"Introducing HPV vaccine in developing countries-key challenges and issues.","volume":"356","author":"Agosti","year":"2007","journal-title":"N Engl J Med"},{"key":"R14-10-20210213","first-page":"10","article-title":"Genital herpes in young adults: Changing sexual behaviours, epidemiology and management.","volume":"12","author":"Roberts","year":"2005","journal-title":"Herpes"},{"key":"R17-10-20210213","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/OLQ.0b013e31813347e9","article-title":"Phase I safety trial of two vaginal microbicide gels (acidform or buffergel) used with a diaphragm compared to KY jelly used with a diaphragm.","volume":"34","author":"Williams","year":"2007","journal-title":"Sex Transm Dis"},{"key":"R18-10-20210213","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1521\/aeap.2007.19.4.310","article-title":"Changes in sexual behavior during a safety and feasibility trial of a microbicide\/diaphragm combination: An integrated qualitative and quantitative analysis.","volume":"19","author":"Guest","year":"2007","journal-title":"AIDS Educ Prev"},{"key":"R19-10-20210213","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.AOG.0000278078.45640.13","article-title":"Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: A randomized controlled trial.","volume":"110","author":"Barnhart","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R20-10-20210213","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.contraception.2007.04.013","article-title":"Delivery of microbicides to the vagina: Difficulties reported with the use of three devices, adherence to use and preferences.","volume":"76","author":"Hardy","year":"2007","journal-title":"Contraception"},{"key":"R21-10-20210213","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/09540120601133576","article-title":"Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.","volume":"19","author":"Joglekar","year":"2007","journal-title":"AIDS Care"},{"key":"R22-10-20210213","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.contraception.2007.05.083","article-title":"Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.","volume":"76","author":"Doh","year":"2007","journal-title":"Contraception"},{"key":"R23-10-20210213","first-page":"266","article-title":"Development and evaluation of a buccal bioadhesive system for smoking cessation therapy.","volume":"62","author":"Garg","year":"2007","journal-title":"Pharmazie"},{"key":"R24-10-20210213","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1086\/513279","article-title":"A comprehensive murine model to evaluate topical vaginal microbicides: Mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.","volume":"195","author":"Galen","year":"2007","journal-title":"J Infect Dis"},{"key":"R25-10-20210213","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/AAC.00984-06","article-title":"Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.","volume":"51","author":"Patton","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-10-20210213","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/AAC.01129-06","article-title":"Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.","volume":"51","author":"Cummins","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-10-20210213","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00002030-199804000-00013","article-title":"Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection.","volume":"12","author":"Van Damme","year":"1998","journal-title":"AIDS"},{"key":"R28-10-20210213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00002030-200001070-00010","article-title":"Safety of multiple daily applications of COL-1492, a nonoxynal-9 vaginal gel among female sex workers.","volume":"14","author":"Van Damme","year":"2000","journal-title":"AIDS"},{"key":"R29-10-20210213","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(02)11079-8","article-title":"Effectiveness of COL-1492, a nonoyxnol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomized trial.","volume":"360","author":"Van Damme","year":"2002","journal-title":"Lancet"},{"key":"R30-10-20210213","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.virusres.2006.04.009","article-title":"The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers.","volume":"121","author":"Marais","year":"2006","journal-title":"Virus Res"},{"key":"R31-10-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000159671.25950.74","article-title":"In vitro and in vivo: The story of nonoxynol 9.","volume":"39","author":"Hillier","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-10-20210213","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.","volume":"13","author":"Jeffrey","year":"2007","journal-title":"Nat Med"},{"key":"R33-10-20210213","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/AAC.00588-06","article-title":"Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.","volume":"50","author":"Trifonova","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-10-20210213","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/QAD.0b013e32801424bd","article-title":"Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding.","volume":"21","author":"Graham","year":"2007","journal-title":"AIDS"},{"key":"R35-10-20210213","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/CAD.0b013e32813148e0","article-title":"The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration.","volume":"18","author":"Lopez","year":"2007","journal-title":"Anticancer Drugs"}],"container-title":["Sexually Transmitted Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007435-200806000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:06:16Z","timestamp":1786035976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007435-200806000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/olq.0b013e31816766af","relation":{},"ISSN":["0148-5717"],"issn-type":[{"value":"0148-5717","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}